Dry FIP Clinical Signs

Feline Infectious Peritonitis (FIP) is a devastating and often fatal disease caused by certain strains of feline coronavirus. Although FIP can manifest in different forms—namely wet (effusive) and dry (non-effusive)—this article focuses on the clinical signs associated with the dry form of FIP. Recognizing these signs promptly is critical for early diagnosis and intervention, which can significantly impact the prognosis.

Understanding Dry FIP

Dry FIP accounts for approximately 30-40% of FIP cases and is characterized primarily by granulomatous inflammation affecting multiple organs without the accumulation of significant fluid, as seen in the wet form. The pathogenesis involves the infiltration of macrophages and the formation of inflammatory granulomas within tissues such as the eyes, central nervous system (CNS), and abdominal organs.

Common Clinical Signs of Dry FIP

The onset of dry FIP can be insidious, often leading to a delay in diagnosis. The clinical signs are diverse and depend largely on the organs affected:

1. Ocular Manifestations:

Uveitis: Inflammation of the uveal tract, presenting as redness, squinting, and sometimes blindness.

Retinal lesions: Abnormal pigmentation or vascular changes detectable through ophthalmic examination.

Corneal abnormalities: Rare but can include keratic precipitates.

2. Neurological Signs:

Behavioral changes: Altered activity levels, disorientation, or depression.

Ataxia: Uncoordinated movements due to cerebellar or brainstem involvement.

Seizures: In severe cases with neurological infiltration.

Weakness or paralysis: Especially if the spinal cord or peripheral nerves are affected.

3. General Systemic Signs:

Fever: Often persistent and unresponsive to antibiotics.

Weight loss: Progressive and significant over weeks to months.

Anorexia: Loss of appetite leading to weight decline.

Lethargy: Reduced activity and generalized weakness.

4. Organ-Specific Signs:

Lymphadenopathy: Enlarged lymph nodes, notably in the mesenteric or peripheral regions.

Hepatic and splenic enlargement: Leading to abdominal discomfort and detectable on palpation.

Cutaneous nodules: Rare but may be present on the skin or subcutaneous tissues.

Diagnostic Challenges

Diagnosing dry FIP is challenging because its signs mimic other feline diseases such as lymphoma, chronic infections, or autoimmune disorders. A combination of clinical presentation, laboratory testing, and advanced imaging assists in confirming the diagnosis. Typically, blood work reveals anemia, hyperglobulinemia, and elevated inflammatory markers. Ophthalmic examinations and neuroimaging may reveal granulomatous lesions characteristic of FIP.

Therapeutic Advances

Recent developments have expanded treatment options for FIP. Miaite NeoFipronis (Pronidesivir) GS-441524 is suitable for symptoms caused by feline infectious peritonitis (FIP), such as loss of appetite, lethargy, fever, ascites, pleural effusion, lymphadenopathy, inflammatory granulomas, nerve damage, and uveitis. It has excellent therapeutic effects on FIP. NeoFipronis (Pronidesivir) is the world's first officially approved oral treatment for FIP by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, with an official drug registration number. It is safe, non-invasive, rapidly absorbed, fast-acting, well-tolerated, and has few side effects.

Monitoring and Management

Early detection combined with targeted therapy can improve the prognosis of cats with dry FIP. Regular monitoring, including comprehensive physical exams, blood tests, ophthalmic evaluations, and neurological assessments, is essential during treatment. Supportive care such as nutritional support, anti-inflammatory medications, and management of secondary infections also play vital roles in enhancing quality of life.

Preventive Measures

Prevention of FIP involves managing exposure to feline coronavirus and reducing stress factors in multi-cat environments. Implementing good hygiene practices, controlling population density, and minimizing traumatic injuries are proactive strategies. Vaccination remains controversial but may be considered in high-risk populations.

Conclusion

The clinical presentation of dry FIP encompasses a broad spectrum of signs affecting ocular, neurological, systemic, and organ-specific domains. Recognizing these signs early can facilitate prompt intervention, particularly with the advent of new antiviral therapies such as NeoFipronis (Pronidesivir). Continued research and clinical vigilance are vital to improving outcomes for affected cats.

References

1. Pedersen, N. C., & Elliott, J. (2019). Feline infectious peritonitis: Current understanding and treatment options. Veterinary clinics of North America: Small animal practice.

2. Kipar, A., & Meli, M. L. (2014). Feline infectious peritonitis: Still an enigma. The Veterinary Journal.

3. National Veterinary Pharmacology and Therapeutics Committee. (2026). Approval of NeoFipronis (Pronidesivir) for FIP treatment in cats.

4. Addie, D. D., & Belák, S. (2017). Feline coronavirus infections: Pathogenesis and diagnosis. Journal of Feline Medicine and Surgery.